mifepristone has been researched along with fluticasone propionate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biggadike, K; Boudjelal, M; Clackers, M; Coe, DM; Demaine, DA; Hardy, GW; House, D; Humphreys, D; Inglis, GG; Johnston, MJ; Jones, HT; Loiseau, R; Macdonald, SJ; McLay, IM; Needham, D; Skone, PA; Uings, I; Veitch, G; Weingarten, GG | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
2 other study(ies) available for mifepristone and fluticasone propionate
| Article | Year |
|---|---|
Nonsteroidal glucocorticoid agonists: tetrahydronaphthalenes with alternative steroidal A-ring mimetics possessing dissociated (transrepression/transactivation) efficacy selectivity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cell Line; Drug Partial Agonism; Humans; Mammary Tumor Virus, Mouse; Models, Molecular; Molecular Mimicry; NF-kappa B; Receptors, Glucocorticoid; Stereoisomerism; Structure-Activity Relationship; Tetrahydronaphthalenes; Transcription, Genetic; Transcriptional Activation | 2007 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |